535 Science Drive
382 articles with Mallinckrodt Pharmaceuticals
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population
Previously presented retrospective analysis showed that adult multiple sclerosis relapse patients taking Acthar Gel had a higher relapse resolution rate than those taking other late-line treatments
Mallinckrodt plc Reports Earnings and Pipeline Advancements for the Third Quarter 2019 and Raises Adjusted Diluted Earnings Per Share Guidance Range for 2019
Net sales of $743.7 million with diluted loss per share from continuing operations of $0.01 and adjusted diluted earnings per share (EPS) of $2.07
Mallinckrodt plc announced the commencement of private offers by its wholly owned subsidiaries, Mallinckrodt International Finance S.A. and Mallinckrodt CB LLC to exchange
Milestone reinforces Company's ongoing strategic efforts to focus on branded, high-growth biopharmaceuticals by monetizing a non-core business
Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System
Approval marks first combined indication label and first regulatory approval in the world for UVADEX in conjunction with the THERAKOS Extracorporeal Photopheresis (ECP) System for the treatment of chronic GvHD in adults
Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week
There are more than 134,000 respiratory therapists in the U.S. Respiratory therapists work closely as part of medical teams to evaluate, treat and care for patients with breathing or other cardiopulmonary disorders.
A conference call for investors will begin at 8:30 a.m. Eastern Time.
10/3/2019Companies from across the globe share information on their business and pipelines.
Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)
An analysis of 148 patients enrolled in the registry showed patients treated with Acthar Gel reported significant improvements in their MS relapse symptoms at 2 months
Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit
Mallinckrodt plc announced that it has executed a definitive settlement agreement and release with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation (MDL) in the U.S. District Court for the Northern District of Ohio
Silence Therapeutics, PLC announces the triggering of the first $2 million in research milestones for SLN500 under the collaboration with Mallinckrodt Pharmaceuticals, a global biopharmaceutical company.
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced positive top-line results from its pivotal Phase 3 clinical trial of its investigational StrataGraft® regenerative tissue.
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the InterContinental New York Barclay, 111 E. 48th St., New York on Wednesday, Oct. 2, 2019.
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse
Retrospective Findings Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and 24th Annual Conference of Rehabilitation in Multiple Sclerosis
Mallinckrodt plc announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc.
Shares of Mallinckrodt are down more than 45% in premarket trading after multiple reports indicate the company plans a restructuring in the wake of the opioid crisis that has promoted a number of lawsuits that implicate the company for its sales practices in the United States.
Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing Activities
Mallinckrodt plc reported the company has finalized a previously disclosed agreement with the U.S. Department of Justice to resolve a civil False Claims Act investigation of Questcor's legacy sales and marketing activities first filed in 2012.
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Tuesday, Sept. 10, 2019, at the Morgan Stanley 17th Annual Global Healthcare Conference at the Grand Hyatt, 109 E. 42nd St., New York.
8/19/2019As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Mallinckrodt plc announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1.